With a rapidly growing global interest in the superpower of exosomes, major pharmaceutical deals and foundational patents, Exopharm is poised to become an essential part of the modern medicine ecosystem.
As the only listed exosome company on the ASX, and one of a small number of exosome companies listed globally, Australian biopharma Exopharm (ASX:EX1) is focused on accelerating its lead in the burgeoning field of exosome-supported modern medicines.
Serial entrepreneur, biomedical engineer, and inventor Dr Ian Dixon founded Exopharm in 2013 to advance exosome medicines by harnessing the natural ability of exosomes to specifically, safely and reliably deliver drugs anywhere in the body.
Fast forward nearly a decade, and Dr Dixon and his team at Exopharm are leading this innovative new class of medicine.
Exopharm’s discoveries in science and engineering enable surface-engineering of exosomes for select-tissue targeting, cargo loading of exosomes for immune-silent drug delivery, and commercial-scale purification and manufacturing of exosomes. Together these exosome technologies fuel the conversion from promise to reality for a range of innovative medicines such as additive gene therapies, gene editing and mRNA therapies.